Licensing opportunities
Discover the innovations we have available for collaboration, that will help create the medicines of tomorrow.
CRT has granted Peptech an exclusive worldwide licence to a panel of cancer therapeutic antibodies for therapeutic, vaccine and in vitro diagnostic use. The antibodies were originally licensed by CRT to UK biotechnology company Scancell Limited (Scancell), who selected two preclinical lead antibodies, SC101 and SC104 for development in colorectal cancer. Peptech has acquired the entire panel of cancer therapeutic antibodies and the intellectual property relating to these programmes from both Scancell and CRT. Scancell is now using the revenue to progress its novel cancer vaccine platform that it co-developed with CRT.
The panel of antibodies was originally developed by Cancer Research UK-funded studies led by Professor Lindy Durrant at the University of Nottingham and targets antigens that are over-expressed on a variety of tumours. SC101 is a mouse monoclonal antibody recognising Lewis y/b. Unlike other known Lewis y/b antibodies, SC101 binds to both haptens on a range of solid tumours and, unusually, does not bind to normal gastrointestinal tract. The antibody has been shown to induce death in tumour cells that over-express Lewis y/b without the need of immune effector cells in vitro. The same cell model has also been used to demonstrate that SC101 inhibits the growth of human colon tumour xenografts and enhances 5-Fluorouracil (5-FU)/leucovorin killing.
SC104 is a novel mouse monoclonal antibody that recognises a cell surface antigen expressed by 90% of colorectal tumours at all clinical stages. It was generated against 4 different colorectal tumour cell lines and antigen characterisation has shown that the antibody recognises an as yet unknown sialyltetraosylceramide. SC104 directly induces tumour-specific cell death without the need for immune effector cells by induction of caspase-mediated apoptosis. The SC104 antibody also kills synergistically with 5FU/leucovorin both in vitro and in vivo.
Financial details of CRT’s agreement with Peptech were not disclosed, but CRT will receive development-based milestones and royalty payments on sales.
Notes to editors
About Peptech Ltd
Peptech Limited is a biotechnology company dedicated to developing and providing antibody and peptide-based human therapeutic products for the treatment of cancer and inflammatory diseases.
The Company has tapped its unique antibody technologies and revenues generated from its pioneering anti-Tumour Necrosis Factor (TNF) patents to build a range of therapeutic assets to address large and clinically validated markets.
Peptech is transitioning to a mid-stage development company as several products move from preclinical into human trials, starting with the Company’s lead product, PN0621, a differentiated anti-TNF based on a domain antibody. For further information: www.peptech.com
About Scancell Ltd
Scancell is developing a vaccine platform that overcomes the present limitations of many therapeutic vaccines. The platform being developed is called an ImmunoBody® and uses a human monoclonal antibody as a vector to target key cells that are essential in stimulating immune responses. Due to the unique modular design of the ImmunoBody® , the stimulus delivered can be customised to make an effective immune response against a specific disease and a specific patient population. This novel invention has been patent protected and is being developed into treatments for various cancers but also has the potential to be applied to the development of vaccines for chronic infections.
Scancell’s first clinical candidate drug , SCIB1, is being developed for the treatment of melanoma. It’s anti-tumour activity has already been validated in vivo and plans are now being put in place to allow the vaccine to be evaluated in patients.
